Dr. Naraev is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10740 Palm River Rd
Ste 360
Tampa, FL 33619Phone+1 813-844-7585Fax+1 813-844-5877
Education & Training
- University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 2009 - 2012
- St Luke's HospitalResidency, Internal Medicine, 2006 - 2009
- Orenburg State Medical Academy Class of 1994
Certifications & Licensure
- CA State Medical License 2008 - 2026
- FL State Medical License 2020 - 2026
- AZ State Medical License 2015 - 2025
- IA State Medical License 2008 - 2025
- MO State Medical License 2008 - 2025
- WA State Medical License 2008 - 2025
- NM State Medical License 2011 - 2021
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- National Board of Physicians and Surgeons Hematology
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013
- Whos Who in Medicine and Healthcare Marquis Whos Who
Publications & Presentations
PubMed
- 23 citationsComparison of Transarterial Liver-Directed Therapies for Low-Grade Metastatic Neuroendocrine Tumors in a Single InstitutionEric Steven Engelman, Roberto A. Leon-Ferre, Boris G. Naraev, Nancy Sharma, Shiliang Sun
Pancreas. 2014-03-01 - 29 citationsPeptide Receptor Radionuclide Therapy for Patients With Advanced Lung CarcinoidsBoris G. Naraev, Robert A. Ramirez, A Tuba Kendi, Thorvardur R. Halfdanarson
Clinical Lung Cancer. 2019-05-01 - 168 citationsMechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma.Sunilkumar Kakadia, Naveen Yarlagadda, Ramez Awad, Madappa N. Kundranda, Jiaxin Niu
Oncotargets and Therapy. 2018-10-17
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: